What is the appropriate imaging work‑up for a patient with elevated norepinephrine, dopamine, and chromogranin A suggesting a catecholamine‑producing tumor?

Imaging Work-Up for Elevated Norepinephrine, Dopamine, and Chromogranin A

Start with contrast-enhanced CT of the abdomen and pelvis as your first-line imaging modality to localize the suspected pheochromocytoma or paraganglioma (PPGL). 1

Initial Anatomical Imaging

The Endocrine Society guidelines explicitly recommend CT over MRI as the first-choice imaging modality due to its excellent spatial resolution for the thorax, abdomen, and pelvis 1. Modern CT can detect tumors as small as 5 mm, and most PPGLs are located in the abdomen, making abdominal/pelvic CT the logical starting point.

Key technical points:

• Use contrast-enhanced CT (nonionic contrast is safe and does not require preoperative alpha-blockade) 1
• CT sensitivity ranges from 88-100% for PPGL detection 1
• Extend imaging to include the chest if initial abdominal imaging is negative, as CT is superior to MRI for detecting lung metastases 1

When to Use MRI Instead

Switch to MRI in these specific scenarios:

• Detection of skull base and neck paragangliomas (sensitivity 90-95%) 1
• Known or suspected metastatic disease 1
• Patients with surgical clips causing CT artifacts 1
• CT contrast allergy 1
• Radiation exposure concerns: children, pregnant women, patients with germline mutations, or recent excessive radiation exposure 1

MRI shows higher sensitivity than CT for extra-adrenal, residual, recurrent, or metastatic tumors (CT sensitivity can drop to 57% in these cases) 1.

Role of Functional Imaging

Functional imaging is NOT routinely necessary for initial localization but has specific indications 2:

Consider functional imaging when:

• Metastatic disease is detected on anatomical imaging and you're planning 131I-MIBG radiotherapy 1
• High-risk features present: large primary tumor, extra-adrenal location, multifocal disease (except skull base/neck), or recurrent disease 1
• Young age (≤40 years) to exclude multiple lesions 2
• SDHB gene mutations to exclude metastatic lesions 2
• Biochemically positive but anatomically negative imaging 2

Functional imaging options:

• 123I-MIBG scintigraphy: Sensitivity 85-88% for pheochromocytomas, 56-75% for paragangliomas 1
• 18F-DOPA PET or FDA-PET: Most successful at identifying disease missed by CT/MRI in metastatic cases (10% and 6.4% additional yield respectively) 3

Important Caveats

Common pitfalls to avoid:

• Up to 50% of normal adrenal glands show physiological 123I-MIBG uptake, leading to false positives 1
• Functional imaging added minimal value in primary cases (only 1.4% additional detection) but was more useful in metastatic cases (3.5% additional detection) 3
• Ultrasound is NOT recommended due to suboptimal sensitivity 1

Imaging Coverage

Scan from skull base to pelvis as standard, since paragangliomas can occur in atypical locations (orbital, cardiac, pericardial, gallbladder, cauda equina) 2. Your patient's elevated dopamine is particularly concerning, as dopamine-secreting PPGLs are often extra-adrenal, larger, and carry higher malignancy risk 4.

Clinical Context for Your Patient

Given the elevation of norepinephrine, dopamine, AND chromogranin A, this biochemical profile strongly suggests PPGL 2. The dopamine elevation warrants particular attention as exclusively or predominantly dopamine-secreting tumors tend to be larger, extra-adrenal, and potentially more aggressive 4. This makes thorough anatomical imaging even more critical, and you should have a lower threshold for extending imaging beyond the abdomen if initial CT is negative or shows concerning features.